Bispecific T cell redirecting antibody(s)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Bispecific T cell redirecting antibody(s), covering 2026-04-13 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma [Phase 1]